Hecla Mining Company Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? Hecla Mining Company Common Stock trades at $15.25 (market cap $10.87B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Hecla Mining Company Common Stock is far larger — about 7.3× uniQure N.V. Ordinary Shares's market cap, and Hecla Mining Company Common Stock pays a 0.09% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hecla Mining Company Common Stock for 3 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| HL | QURE | |
|---|---|---|
Market Cap | $10.87B | $1.48B |
Volume | 31,516,848 | 2,488,780 |
Sector | Basic Materials | Health |
52-Week High | $31.81 | $70.59 |
52-Week Low | $11.97 | $9.03 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $10.40B | $728.62M |
Dividend Yield | 0.09% | — |
Signals from Pluang's Aura AI — not financial advice
Hecla Mining (HL) trades at $16.18, down 3.92% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 51.68% gross margin and 19.15% net income margin, but recent quarterly earnings missed expectations. Positive news highlights a debt-free balance sheet and organic growth targeting over 20 million silver ounces, while institutional activity includes new investments from Bank of America and AlphaGrep.
The outlook is mixed: analyst consensus is a Buy with a $23.44 price target, implying 45% upside, but technical indicators signal near-term pressure. Key risks include silver price volatility and execution of growth projects. The stock presents a value opportunity for long-term investors if operational targets are met.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hecla Mining is a precious metals producer focused on silver and gold. It operates mines in the United States and Canada.
Read more on HL →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →